Optimizing patient therapy: the role of bone markers?

Cancer Treatment Reviews

Volumn 32, Issue SUPPL. 1, 2006, Pages 3-6

  Saad, Fred ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Biochemical bone turnover markers; Bisphosphonates; Matastatic bone disease; Quality of life; Skeletal related events; Zoledronic acid

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ARTICLE; BLADDER CARCINOMA; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE TURNOVER; BREAST CARCINOMA; CANCER RADIOTHERAPY; CLINICAL TRIAL; CORRELATION ANALYSIS; HUMAN; HYPERCALCEMIA; IMMOBILIZATION; INDIVIDUALIZATION; KIDNEY DISEASE; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PATHOLOGIC FRACTURE; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PROSTATE CARCINOMA; QUALITY OF LIFE; RISK ASSESSMENT; SPINAL CORD COMPRESSION; THYROID CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 33646262879     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(06)80002-2     Document Type: Article

References (19)

1. Saad F., Olsson C., and Schulman C. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 46 (2004) 731-739
2. Delea T., Langer C., McKiernan J., et al. The cost of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67 (2004) 390-396
3. Coleman R. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94 (2002) 2521-2533
4. Abstract. Kurth H., McKiernan J., Bentkover J., and Thomas S. Quality of life and pain among prostate cancer patients with bone metastases. J Clin Oncol 23 June 1 Suppl, (2005) 4747
5. Abstract 662P. Weinfurt K., Li Y., Castel L., Timbie J., Glendenning A., and Schulman K. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 13 Suppl 5 (2002) 180
6. Weinfurt K., Li Y., Castel L., et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16 (2005) 579-584
7. Oefelein M., Ricchiuti V., Conrad W., and Resnick M. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168 (2002) 1005-1007
8. Hortobagyi G., Theriault R., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335 (1996) 1785-1791
9. Fleisch H. Development of bisphosphonates. Breast Cancer Res 4 (2002) 30-34
10. Coleman R. Bisphosphonates in breast cancer. Ann Oncol 16 (2005) 687-695
11. Lipton A., Small E., Saad F., et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20 Suppl 2 (2002) 45-54
12. Roemer-Becuwe C., Krakowski I., and Conroy T. Bisphosphonates, pain and quality of life in metastatic breast cancer patients: a literature review. Bull Cancer 90 (2003) 1097
13. Saad F., Gleason D., Murray R., et al., Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
14. Saad F. Clinical benefit of zeledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 4 (2005) 31-37
15. Rosen L., Gordon D., Tchekmedyian N., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase Ill, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
16. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23 (2005) 3314-3321
17. Body J., Diel I., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111 (2004) 306-312
18. Abstract. Kretzschmar A., Wiegel T., Al-Batran S., et al. Zoledronic acid (Z) as palliative treatment in cancer patients with bone metastases: interim results of a prospective, open-label trial. J Clin Oncol 22 July 15 Suppl (2004) 8140
19. Rosen L., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer. Cancer 98 (2003) 1735-1744